In vitropharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms | Zendy

Sherwin K. B. Sy | Zendy; MarieEve Beaudoin | Zendy; Luning Zhuang | Zendy; Kathrin I. Löblein | Zendy; Clemens Lux | Zendy; Marlene Kissel | Zendy; Robin Tremmel | Zendy; Christian Frank | Zendy; Severin Strasser | Zendy; Jules A. A. C. Heuberger | Zendy; Midas B. Mulder | Zendy; Virna Schuck | Zendy; Hartmut Derendorf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitropharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms

Author(s) -

Sherwin K. B. Sy,

MarieEve Beaudoin,

Luning Zhuang,

Kathrin I. Löblein,

Clemens Lux,

Marlene Kissel,

Robin Tremmel,

Christian Frank,

Severin Strasser,

Jules A. A. C. Heuberger,

Midas B. Mulder,

Virna Schuck,

Hartmut Derendorf

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw082

Subject(s) - aztreonam , avibactam , microbiology and biotechnology , pharmacokinetics , pharmacology , pharmacodynamics , medicine , chemistry , antibiotics , biology , klebsiella pneumoniae , biochemistry , antibiotic resistance , escherichia coli , imipenem , gene

The combination of aztreonam and avibactam has been proposed for the treatment of infections caused by metallo-β-lactamase-producing Gram-negative organisms, given the stability of aztreonam against metallo-β-lactamases plus the broad coverage of avibactam against AmpC β-lactamases and ESBLs. This study aimed to evaluate the efficacy of the combination against four clinical isolates with defined but diverse β-lactamase profiles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research